Very quiet here for a stock that looks like it's on the launch pad. Possibly replacing expensive biopsy procedures with diagnostic testing sounds like a win/win for patients and insurance providers. Nice chart with long base, with any traction in sales, I could easily see OCX becoming a double digit stock.
News 
Market Data 
Discover 
